

Press Release

14 August 2025 11:00:00 CEST

Mubadala Health Dubai Invests in Precision Diagnostics with Qlucore Insights for Lung Cancer and Pediatric Leukemia

Qlucore, a driving force in software development for precision diagnostics, has signed an agreement with Mubadala Health Dubai. They will use Qlucore Insights software for the analysis of cancer samples.

Cancer diagnostics are changing rapidly, and Qlucore is at the forefront of this development. The Qlucore software, unique in its field, combines advanced visualization, AI-based machine learning and biology to improve performance as well as ease of use and speed. Qlucore Insights leverages whole transcriptomic data generated through next-generation sequencing to derive results. The solution is easy to deploy as it is based on basic lab workflows and instruments. The program operates on-premises, ensuring enhanced data security.

Lung cancer remains one of the most challenging diseases to diagnose and treat effectively. With Qlucore Insights, Mubadala Health Dubai aims to improve lung cancer diagnostics.

"Our solution will facilitate and enable analysis of cancer samples. The goal is to make it easier for the doctor to make a diagnosis and decide how the disease should be treated, and for the patients to receive more precise treatment," says Carl-Johan Ivarsson, CEO of Qlucore.

In addition to Qlucore Insights test for lung cancer samples, Mubadala Health Dubai has also purchased Qlucore Insights for analysis of pediatric leukemia (BCP-ALL). This dual application underscores the versatility and robustness of Qlucore's software in addressing various cancer types.

Qlucore Insights is for research use only.

Certified Advisor

FNCA Sweden AB

Web: www.fnca.se

Qlucore Sweden Ideon Science Park, Scheelevägen 17, 223 70 Lund.

Qlucore USA 250 W 55th Street, 17th Floor, New York, NY 10019.

Contacts

Press contact:

Maria Falck Miniotis, Marketing & Communications Manager

Phone: +46 (0) 736 10 26 65

Email: maria.falck@qlucore.com

Carl-Johan Ivarsson, CEO

Phone: +46 (0) 46 286 31 10

Email: carl-johan.ivarsson@qlucore.com

About QluCore

QluCore is a leading provider of new generation intuitive bioinformatics software for research and precision and companion diagnostics. QluCore's mission is to make it easier to analyze the huge amounts of complex data generated by innovations in the fields of genomics and proteomics by providing powerful visualization-based bioinformatics data analysis tools for research and precision diagnostics. QluCore Omics Explorer software is a easy to use bioinformatics software for research in the life science, plant- and biotech industries, as well as in academia. QluCore Diagnostics and QluCore Insights are software platforms with built in AI-based machine learning for multi-omics companion and precision diagnostics. QluCore was founded in 2007 in Lund, Sweden and has customers in about 20 countries around the world, with sales offices in Europe and North America, and distribution in several countries in Asia. QluCore is listed on the Nasdaq First North Growth market. www.qlucore.com

About Stockholm Corporate Finance AB

Stockholm Corporate Finance AB is an independent, privately owned financial advisor offering services in qualified advisory related to capital raising, ownership changes, acquisitions, mergers, divestments (M&A), and flexible debt solutions (Private Debt) for publicly listed and private companies and their owners. Stockholm Corporate Finance is a securities company under the supervision of the Swedish Financial Supervisory Authority (Finansinspektionen) and a member of the industry organization SwedSec Licensiering AB. www.stockholmcorp.se

Attachments

[Mubadala Health Dubai Invests in Precision Diagnostics with QluCore Insights for Lung Cancer and Pediatric Leukemia](#)